• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[基层医疗中的哮喘治疗:我们是否遵循了国际共识(《全球哮喘防治创议2002》)?]

[Primary care asthma treatment: Are we following international consensus (GINA 2002)?].

作者信息

Flor Xavier, Alvarez Isabel, Martín Eva, Castan Xavier, Maria Vigatà Josep, Rodríguez Montserrat, Orfila Francesc, Fernández Eladi

机构信息

Medicina Familiar y Comunitaria CAP Chafarinas, SAP Muntanya, Barcelona, España.

出版信息

Aten Primaria. 2006 Jun 15;38(1):19-24. doi: 10.1157/13090025.

DOI:10.1157/13090025
PMID:16790214
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7676109/
Abstract

OBJECTIVE

To check whether treatment of asthma patients at our centre coincides with international criteria (GINA 2002).

DESIGN

Transversal, descriptive study.

SETTING

Urban primary care team.

PARTICIPANTS

Asthma patients over 14 years old.

MAIN MEASUREMENTS

Review of clinical histories (CH) and analysis of the last prescription between November 2002 and May 2003.

RESULTS

We reviewed 436 CH, of which 395 made up the study group. 71.4% (SD, 66.9-75.8) were women. Average age was 51.4 (SD, 49.2-53.6). Classification of asthma as function of gravity was: intermittent (IA): 30% (25.7-34.3); light persistent (LPA): 24.8% (20.7-28.8); moderate persistent (MPA): 30.7% (26.4-35.1); serious persistent (SPA): 5.05% (3.19-7.54). Unclassified: 9.4% (6.83-12.5). Correct treatment: IA, 69.5% (61.6-77.4); LPA, 22.2% (14.4-30.1); MPA, 46.2% (7.8-54.7); SPA, 72.7% (49.8-89.3). The most common cause of incorrect treatment in all kinds of asthma was the use of international criteria (IC) at inadequate doses: IA, 47.5% (31.5-63.9); LPA, 73.8% (63.1-82.8); MPA, 38.9% (27.6-51.1); SPA, 33.3% (4.3-77.7). The scant use of B2CD.AD was noticeable: IA, 47.5% (31.5-63.9); LPA, 85.7% (76.4-92.4); MPA, 86.7% (74.3-92.1); SPA, 66.7% (22.3-95.7). The most commonly used active principles were salbutamol, salmeterol, budesonide, and montelukast. On overall measurement of good treatment, we found that 48.9% (n = 193) of patients had a correct prescription.

CONCLUSIONS

In primary care, light forms of asthma are most commonly monitored. We found low concordance with the GINA 2002 directives. IC are widely used, but often at incorrect doses. We insist on the importance of classifying asthma according to its gravity in order to prescribe the right treatment.

摘要

目的

检查我们中心对哮喘患者的治疗是否符合国际标准(《全球哮喘防治创议》2002年版)。

设计

横断面描述性研究。

地点

城市基层医疗团队。

参与者

14岁以上的哮喘患者。

主要测量指标

回顾临床病史(CH)并分析2002年11月至2003年5月期间的最后一张处方。

结果

我们回顾了436份临床病史,其中395份构成研究组。71.4%(标准差,66.9 - 75.8)为女性。平均年龄为51.4岁(标准差,49.2 - 53.6)。根据病情严重程度对哮喘的分类为:间歇性(IA):30%(25.7 - 34.3);轻度持续性(LPA):24.8%(20.7 - 28.8);中度持续性(MPA):30.7%(26.4 - 35.1);重度持续性(SPA):5.05%(3.19 - 7.54)。未分类:9.4%(6.83 - 12.5)。正确治疗情况:IA,69.5%(61.6 - 77.4);LPA,22.2%(14.4 - 30.1);MPA,46.2%(7.8 - 54.7);SPA,72.7%(49.8 - 89.3)。各类哮喘治疗不正确的最常见原因是国际标准药物(IC)剂量不足:IA,47.5%(31.5 - 63.9);LPA,73.8%(63.1 - 82.8);MPA,38.9%(27.6 - 51.1);SPA,33.3%(4.3 - 77.7)。β2激动剂使用较少值得注意:IA,47.5%(31.5 - 63.9);LPA,85.7%(76.4 - 92.4);MPA,86.7%(74.3 - 9

相似文献

1
[Primary care asthma treatment: Are we following international consensus (GINA 2002)?].[基层医疗中的哮喘治疗:我们是否遵循了国际共识(《全球哮喘防治创议2002》)?]
Aten Primaria. 2006 Jun 15;38(1):19-24. doi: 10.1157/13090025.
2
Prescriptive adherence to GINA guidelines and asthma control: An Italian cross sectional study in general practice.按照 GINA 指南进行规范治疗与哮喘控制:意大利普通实践中的一项横断面研究。
Respir Med. 2019 Jan;146:10-17. doi: 10.1016/j.rmed.2018.11.001. Epub 2018 Nov 16.
3
Compliance with guidelines in the treatment of asthma exacerbations in primary care.在初级保健中治疗哮喘加重时对指南的遵循情况。
Ther Adv Respir Dis. 2011 Dec;5(6):369-75. doi: 10.1177/1753465811416698. Epub 2011 Sep 15.
4
The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey.作为全球哮喘防治创议(GINA)指南定义的哮喘控制指标预测工具的哮喘控制测试(ACT):一项跨国横断面调查分析
Prim Care Respir J. 2009 Mar;18(1):41-9. doi: 10.4104/pcrj.2009.00010.
5
Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study).未控制哮喘患者的随访:根据达到的控制水平(COAS 研究)评估哮喘患者的临床特征。
Eur Respir J. 2017 Mar 2;49(3). doi: 10.1183/13993003.01885-2015. Print 2017 Mar.
6
Asthma symptoms, morbidity, and antiinflammatory use in inner-city children.城市中心区儿童的哮喘症状、发病率及抗炎药物使用情况
Pediatrics. 2001 Aug;108(2):277-82. doi: 10.1542/peds.108.2.277.
7
Control of persistent asthma in Spain: associated factors.西班牙持续性哮喘的控制:相关因素
J Asthma. 2008 Nov;45(9):740-6. doi: 10.1080/02770900802216783.
8
Validation of the Spanish version of the Asthma Control Questionnaire.哮喘控制问卷西班牙语版本的验证
Clin Ther. 2008 Oct;30(10):1918-31. doi: 10.1016/j.clinthera.2008.10.005.
9
Documenting asthma severity: do we get it right?记录哮喘严重程度:我们做得对吗?
J Asthma. 2003 Sep;40(6):661-5. doi: 10.1081/jas-120019037.
10
[Asthma control status in Tunisia].[突尼斯的哮喘控制状况]
Tunis Med. 2010 Feb;88(2):97-101.

本文引用的文献

1
Asthma guidelines: recommendations versus reality.
Respir Med. 2004 Apr;98 Suppl A:S1-7. doi: 10.1016/j.rmed.2004.02.002.
2
[Do we forget asthma as a chronic illness in our primary care consultations?].在我们的初级保健会诊中,我们是否忽略了哮喘是一种慢性病?
Aten Primaria. 2004 Apr 30;33(7):381-6. doi: 10.1016/s0212-6567(04)78890-3.
3
Classifying asthma: disagreement among specialists.
Chest. 2003 Dec;124(6):2156-63. doi: 10.1378/chest.124.6.2156.
4
An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing.布地奈德/福莫特罗个体化、可调整的维持治疗方案,以低于固定剂量的总剂量有效控制哮喘症状。
Swiss Med Wkly. 2003 May 31;133(21-22):302-9. doi: 10.4414/smw.2003.10229.
5
One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma.布地奈德/福莫特罗单吸入器(信必可都保)治疗哮喘的一年安全性和疗效
Respir Med. 2003 Jun;97(6):702-8. doi: 10.1053/rmed.2003.1504.
6
Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence.吸入性糖皮质激素与白三烯受体拮抗剂作为单一药物治疗哮喘:当前证据的系统评价
BMJ. 2003 Mar 22;326(7390):621. doi: 10.1136/bmj.326.7390.621.
7
Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.长效β受体激动剂常规治疗与短效β受体激动剂每日常规治疗用于稳定期哮喘成人和儿童的比较
Cochrane Database Syst Rev. 2002;2002(4):CD003901. doi: 10.1002/14651858.CD003901.
8
Lay versus professional motivation for asthma treatment: a cross-sectional, qualitative study in a single Glasgow general practice.
Fam Pract. 2002 Apr;19(2):172-7. doi: 10.1093/fampra/19.2.172.
9
Fluticasone versus beclomethasone or budesonide for chronic asthma.氟替卡松与倍氯米松或布地奈德治疗慢性哮喘的比较。
Cochrane Database Syst Rev. 2002(1):CD002310. doi: 10.1002/14651858.CD002310.
10
[The use of the International Guidelines for the Diagnosis and Treatment of Asthma (GINA) in clinical practice among family physicians].家庭医生临床实践中哮喘诊断与治疗国际指南(GINA)的应用
Rev Alerg Mex. 2001 Nov-Dec;48(6):159-62.